Latest News
Omeros receives negative EU opinion on narsoplimab after re-examination
16 October 2026 - Biotechnology company Omeros Corporation (Nasdaq:OMER) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) maintained its negative opinion on the marketing authorisatio...
Ionis' TRYNGOLZA recommended for EU approval in severe hypertriglyceridemia
16 October 2026 - Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of TRYNGOLZA (olezarsen) for ...
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
16 October 2026 - Swedish medical device company VibroSense Dynamics AB (Spotlight Stock Market: VSD B), which develops tools for diagnosing nerve damage in the hands and feet, said on Friday it has received regulatory approval in Thailand for VibroS...
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
16 October 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that it has received US Food and Drug Administration (FDA) approval for Enspryng (satralizumab-mwge) to treat adults wit...
IBA and Framatome establish joint venture to scale up Astatine-211 production
16 October 2026 - Particle accelerator technology company Ion Beam Applications S.A. (IBA) (Euronext Brussels:IBAB) announced on Friday that together with French nuclear energy company Framatome it has established Ekalia, a joint venture focused on b...